Bimonthly cranial MRI activity following an isolated monosymptomatic demyelinating syndrome: Potential outcome measures for future multiple sclerosis 'prevention' trials

Multiple Sclerosis

Volumn 5, Issue 5, 1999, Pages 307-312

  Kinkel, R P ^a   Simon, J H ^b   Baron, B ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Department of Pathology   (United States)

Author keywords

Brainstem syndrome; Contrast media; Magnetic resonance imaging; Multiple sclerosis; Optic neuritis; Partial transverse myelitis

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY;

EID: 0032701930     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859900500501     Document Type: Article

References (27)

1. Miller DH et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 39: 6-16.
2. Simon JH. (1996) Magnetic resonance imaging of multiple sclerosis lesions: Measuring outcome in treatment trials. West J Med 164: 502-509.
3. Simon JH. (1997) Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. JMRI 7: 29-37.
4. Morissey SP et al. (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of MS. A five year follow-up study. Brain 116: 135-146.
5. Filippi M et al. (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44: 635-641.
6. Optic Neuritis Study Group. (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49: 1404-1413.
7. Jacobs LD et al. (1997) Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 41: 392-398.
8. Barkhof F et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120: 2059-2069.
9. Miller DH et al. (1989) The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord. Ann Neurol 26: 635-639.
10. Beck RW et al. (1993) Optic neuritis study group. Brain magnetic resonance imaging in acute optic neuritis. Experience of the optic neuritis study group. Arch. Neurol 50: 841-846.
11. Wiebe S et al. (1992) Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol 32: 643-650.
12. Simon JH et al. (1998) Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 43: 79-87.
13. Filippi M et al. (1996) Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 46: 379-384.
14. Silver NC et al. (1997) Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 120: 1149-1161.
15. Wolansky LJ et al. (1994) Triple-dose versus single dose gadoteridol in Multiple Sclerosis patients. J Neuroimag 4(3): 141-145.
16. Tas MW et al. (1995) The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. AJNR 16: 259-264.
17. Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285-294.
18. Filippi M et al. (1997) Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. AJNR 18: 1549-1556.
19. Goodkin DE et al. (1996) Low dose oral methotrexate in chronic progressive multiple sclerosis. Analyses of serial MRIs. Neurology 47: 1153-1157.
20. Miki Y et al. (1997) Computer-assisted quantitation of enhancing lesions in multiple sclerosis: Correlation with clinical classification. AJNR 18: 705-710.
21. Nauta JJP, Thompson AJ, Brakhof F, Miller DH. (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 122: 6-14.
22. Koudriavtseva T et al. (1997) Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neuosurg Psych 62(3): 285-287.
23. McFarland HF et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758-766.
24. Lai HM et al. (1996) A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psych 60: 339-341.
25. Paty DW, Li DKB, the UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, pacebo-controlled trial. Neurology 43: 662-667.
26. 2-weighted brain MRI activity in multiple sclerosis: A follow-up study. Neurology 45: 255-260.
27. Miller DH, Barkhof F, Nauta JFF. (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116: 1077-1094.